Viatris has urged shareholders to reject an unsolicited, below-market mini-tender offer from TRC Capital Corporation, the latest made by the infamous Canadian investor, whose tactics have received sharp criticism from companies and the US Securities and Exchange Commission alike.
Viatris Comes Out Swinging At Unsolicited Mini-Tender Offer
TRC Capital Makes Discounted Offer For Millions Of Shares
TRC Capital Corporation, famed for making discounted offers to buy shares well below the SEC’s 5% threshold, has approached Viatris shareholders. The newly-formed company, like many others, has urged shareholders to say no.
More from Deals
More from Business
• By
Generics Bulletin previews the most noteworthy and anticipated events for May 2025.
• By
Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.
• By
Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.